The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
Open accessAbstract
Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human dendritic cells (DC) by combining microarray, mRNA and protein multiplex assays and flow cytometry analyses. We demonstrate that GLA has multifunctional immunomodulatory activity similar to naturally-derived monophosphory lipid A (MPL) on murine DC, including the production of inflammatory cytokines, chemokines, DC maturation and antigen-presenting functions. In contrast, hexaacylated GLA was overall more potent on a molar basis than heterogeneous MPL when tested on human DC and peripheral blood mononuclear cells (PBMC). When administered in vivo, GLA enhanced the immunogenicity of co-administered recombinant antigens, producing strong cell-mediated immunity and a qualitative T(H)1 response. We conclude that the GLA adjuvant stimulates and directs innate and adaptive immune responses by inducing DC maturation and the concomitant release of pro-inflammatory cytokines and chemokines associated with immune cell trafficking, activities which have important implications for the development of future vaccine adjuvants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
LPS/TLR4 signal transduction pathway
Lu, Y.-C., Yeh, W.-C., & Ohashi, P. S. (2008) · Cytokine · doi:10.1016/j.cyto.2008.01.006 · Cited by 3,301
The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling
O'Neill, L. A. J., & Bowie, A. G. (2007) · Nature Reviews Immunology · doi:10.1038/nri2079 · Cited by 2,667
The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex
Park, B. S., Song, D. H., Kim, H. M., Choi, B.-S., Lee, H., & Lee, J.-O. (2009) · Nature · doi:10.1038/nature07830 · Cited by 2,428
Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran
Kim, H. M., Park, B. S., Kim, J.-I., Kim, S. E., Lee, J., Oh, S. C., Enkhbayar, P., Matsushima, N., Lee, H., Yoo, O. J., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.002 · Cited by 1,177
Bacterial lipopolysaccharides and innate immunity
Alexander, C., & Rietschel, E. T. (2001) · Journal of Endotoxin Research · doi:10.1179/096805101101532675 · Cited by 1,120
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
Mata-Haro, V., Cekic, C., Martin, M., Chilton, P. M., Casella, C. R., & Mitchell, T. C. (2007) · Science · doi:10.1126/science.1138963 · Cited by 896
Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development
Pulendran, B., & Ahmed, R. (2006) · Cell · doi:10.1016/j.cell.2006.02.019 · Cited by 625
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
Self-citationNew horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Self-citationAdjuvants — a balance between toxicity and adjuvanticity
Gupta, R. K., Relyveld, E. H., Lindblad, E. B., Bizzini, B., Ben-Efraim, S., & Gupta, C. K. (1993) · Vaccine · doi:10.1016/0264-410x(93)90190-9 · Cited by 545
Tuberculosis: Latency and Reactivation
Flynn, J. L., & Chan, J. (2001) · Infection and Immunity · doi:10.1128/iai.69.7.4195-4201.2001 · Cited by 500
Crystal Structures of Human MD-2 and Its Complex with Antiendotoxic Lipid IVa
Ohto, U., Fukase, K., Miyake, K., & Satow, Y. (2007) · Science · doi:10.1126/science.1139111 · Cited by 471
Khader, S. A., Partida-Sanchez, S., Bell, G., Jelley-Gibbs, D. M., Swain, S., Pearl, J. E., Ghilardi, N., deSauvage, F. J., Lund, F. E., & Cooper, A. M. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052545 · Cited by 335
Exploiting dendritic cells to improve vaccine efficacy
Steinman, R. M., & Pope, M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15962 · Cited by 319
Exploiting dendritic cells to improve vaccine efficacy
Steinman, R. M., & Pope, M. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215962 · Cited by 268
Human MD-2 confers on mouse Toll-like receptor 4 species-specific lipopolysaccharide recognition
Akashi, S., Nagai, Y., Ogata, H., Oikawa, M., Fukase, K., Kusumoto, S., Kawasaki, K., Nishijima, M., Hayashi, S., Kimoto, M., et al. (2001) · International Immunology · doi:10.1093/intimm/13.12.1595 · Cited by 245
Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529
Evans, J. T., Cluff, C. W., Johnson, D. A., Lacy, M. J., Persing, D. H., & Baldridge, J. R. (2003) · Expert Review of Vaccines · doi:10.1586/14760584.2.2.219 · Cited by 243
Structural and functional analyses of bacterial lipopolysaccharides
Caroff, M., Karibian, D., Cavaillon, J.-M., & Haeffner-Cavaillon, N. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(02)01612-x · Cited by 211
Toll-like Receptor 2 Senses β-Cell Death and Contributes to the Initiation of Autoimmune Diabetes
Kim, H. S., Han, M. S., Chung, K. W., Kim, S., Kim, E., Kim, M. J., Jang, E., Lee, H. A., Youn, J., Akira, S., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.010 · Cited by 195
Bertholet, S., Ireton, G. C., Kahn, M., Guderian, J., Mohamath, R., Stride, N., Laughlin, E. M., Baldwin, S. L., Vedvick, T. S., Coler, R. N., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.7948 · Cited by 169
Self-citationMonophosphoryl Lipid A (MPL) Formulations for the Next Generation of Vaccines
Baldridge, J. R., & Crane, R. T. (1999) · Methods · doi:10.1006/meth.1999.0834 · Cited by 168
Dual Signaling of MyD88 and TRIF Is Critical for Maximal TLR4-Induced Dendritic Cell Maturation
Shen, H., Tesar, B. M., Walker, W. E., & Goldstein, D. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1849 · Cited by 160
Evaluation of RTS,S/AS02A and RTS,S/AS01B in Adults in a High Malaria Transmission Area
Polhemus, M. E., Remich, S. A., Ogutu, B. R., Waitumbi, J. N., Otieno, L., Apollo, S., Cummings, J. F., Kester, K. E., Ockenhouse, C. F., Stewart, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006465 · Cited by 157
A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
Coler, R. N., Baldwin, S. L., Shaverdian, N., Bertholet, S., Reed, J., Raman, V. S., Lu, X., DeVos, J. R., Hancock, K., Katz, J. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013677 · Cited by 150
Self-citationElucidation of the MD-2/TLR4 Interface Required for Signaling by Lipid IVa
Walsh, C., Gangloff, M., Monie, T. P., Smyth, T., Wei, B., McKinley, T. J., Maskell, D. J., Gay, N. J., & Bryant, C. E. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1245 · Cited by 119
Optimized subunit vaccine protects against experimental leishmaniasis
Bertholet, S., Goto, Y., Carter, L. P., Bhatia, A., Howard, R. F., Carter, D., Coler, R. N., Vedvick, T. S., & Reed, S. G. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.09.066 · Cited by 106
Self-citationPhysicochemical characterization and biological activity of synthetic TLR4 agonist formulations
Anderson, R. C., Fox, C. B., Dutill, T. S., Shaverdian, N., Evers, T., Poshusta, G. R., Chesko, J., Coler, R. N., Friede, M., Reed, S. G., et al. (2009) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2009.08.022 · Cited by 105
Self-citationVaccinology at the beginning of the 21st century
Wack, A., & Rappuoli, R. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.05.005 · Cited by 104
Selective Activation of the p38 MAPK Pathway by Synthetic Monophosphoryl Lipid A
Cekic, C., Casella, C. R., Eaves, C. A., Matsuzawa, A., Ichijo, H., & Mitchell, T. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.046383 · Cited by 104
Baldwin, S. L., Shaverdian, N., Goto, Y., Duthie, M. S., Raman, V. S., Evers, T., Mompoint, F., Vedvick, T. S., Bertholet, S., Coler, R. N., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.081 · Cited by 101
Self-citationIntradermal immunization improves protective efficacy of a novel TB vaccine candidate
Baldwin, S. L., Bertholet, S., Kahn, M., Zharkikh, I. L., Ireton, G. C., Vedvick, T. S., Reed, S. G., & Coler, R. N. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.018 · Cited by 98
Self-citationRallabhandi, P., Awomoyi, A. A., Thomas, K. E., Phalipon, A., Fujimoto, Y., Fukase, K., Kusumoto, S., Qureshi, N., Sztein, M. B., & Vogel, S. N. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.1139 · Cited by 88
Fox, C. B., Anderson, R. C., Dutill, T. S., et al. (2008) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2008.03.003 · Cited by 83
Self-citationNascimento, E., Fernandes, D. F., Vieira, E. P., et al. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.063 · Cited by 81
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis
Vélez, I. D., Gilchrist, K., Martínez, S., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.10.045 · Cited by 77
Lipid A diversity and the innate host response to bacterial infection
Darveau, R. P. (1998) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(98)80140-9 · Cited by 71
Structural Regions of MD-2 That Determine the Agonist-Antagonist Activity of Lipid IVa
Muroi, M., & Tanamoto, K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509193200 · Cited by 67
Synthetic and Natural TLR4 Agonists as Safe and Effective Vaccine Adjuvants
Fox, C. B., Friede, M., Reed, S. G., & Ireton, G. C. (2010) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-90-481-9078-2_14 · Cited by 66
Self-citationThe development and use of vaccine adjuvants
Edelman, R. (2002) · Molecular Biotechnology · doi:10.1385/mb:21:2:129 · Cited by 66
Qureshi, N., Kaltashov, I. A., Walker, K. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10594 · Cited by 62
Raman, V. S., O’Donnell, J. A., Bailor, H. R., Goto, W., Lahiri, R., Gillis, T. P., Reed, S. G., & Duthie, M. S. (2009) · Infection and Immunity · doi:10.1128/iai.00508-09 · Cited by 25
Self-citation
Cited by
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi-Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 338
Mazur, N. I., Martinón-Torres, F., Baraldi, E., Fauroux, B., Greenough, A., Heikkinen, T., Manzoni, P., Mejias, A., Nair, H., Papadopoulos, N. G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00255-6 · Cited by 296
Sweeten PAMPs: Role of sugar complexed PAMPs in innate immunity and vaccine biology
Mahla, R. S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00248 · Cited by 239
Kwissa, M., Nakaya, H. I., Oluoch, H., & Pulendran, B. (2012) · Blood · doi:10.1182/blood-2011-10-388579 · Cited by 132
Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection
Merani, S., Pawelec, G., Kuchel, G. A., & McElhaney, J. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00784 · Cited by 74
“It has also been shown in vitro that GLA can induce the maturation of human DCs with an associated release of Th1-inducing cytokine and chemokine constellation (187).”
Background
Metadata
- Authors
- Coler, R. N., Bertholet, S., Moutaftsi, M., Guderian, J. A., Windish, H. P., Baldwin, S. L., Laughlin, E. M., Duthie, M. S., Fox, C. B., Carter, D., Friede, M., Vedvick, T. S., & Reed, S. G.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-26
- Volume
- 6
- Issue
- 1
- Pages
- e16333
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2094933901
- Cited by
- 312
- References
- 43
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.